MedTrace Logo

The Isthmus Logic Post Market Clinical Follow-up Study

NCT05616143 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-11-15

No results posted yet for this study

Summary

Isthmus Logic Carbostent™ is a CE-marked cobalt chromium stent with a bio inducer surface for the treatment of peripheral iliac artery disease.

The aim of this post-market retrospective study protocl P22202 is to collect clinical data of patients treated with Isthmus Logic for the treatment of peripheral iliac artery disease in routine clinical practice.

In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with these devices at least 12 months prior to the study start.

Conditions

  • Peripheral Arterial Disease

Interventions

DEVICE

Isthmus Logic

Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease

Sponsors & Collaborators

  • Meditrial Europe Ltd.

    collaborator INDUSTRY

  • CID S.p.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-06-30
Completion
2023-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616143 on ClinicalTrials.gov